TNFRSF8 and primary cutaneous T-cell non-Hodgkin lymphoma: Some promising results have been seen with use of brentuximab vedotin, a CD30-directed immunotoxin, in CD30-positive PTCL and CTCL [16, 17] and the use of pembroluzimab, a programmed cell death receptor 1 (PD-1) inhibitor, in the treatment of ENKTL [18]; however, these positive results have been limited to very specific subsets of T cell disease.